301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
The Readout Loud
00:00
Introduction
Exploring a biotech mega-round through a reverse merger and a pipe, along with insights from Arruka Therapeutic's CEO on recent life sciences advancements like the conclusion of the Amalix ALS case, new applications for GLP1s, and hurdles in gene editing plans. The chapter wraps up with a sponsor message urging listeners to subscribe to Stat's HealthCare Inc newsletter.
Transcript
Play full episode
